13th Euro Abstracts A285 a 26-week, randomized, clinical trial in 456 patients with type 2 diabetes failing treatment with oral antidiabetic agents (OAD) was performed to compare EQW to insulin glargine. EQW and insulin glargine were associated with (LS) mean decreases in HbA1c (−1.47% and −1.31%), decreases in systolic blood pressure (−3.03 mmHg and −0.63 mmHg), and changes in body weight (−2.6 kg and +1.4 kg) from baseline, respectively. METHODS: The published and validated CORE Diabetes Model (CDM) was used to project clinical outcomes over patient lifetimes using the trial data. The model simulates disease progression by combining 15 Markov-based submodels to determine the occurrence and time to onset of diabetes-related complications, life-years gained, and qualityadjusted life-years (QALYs). Standard CDM utility values for diabetes-related complications and weight were included in the model. a discount rate of 3.5% was applied. RESULTS: Treatment with EQW compared to insulin glargine was associated with a higher life expectancy (11.91 vs. 11.81 years) and quality-adjusted life expectancy (8.019 vs. 7.846 QALYs). The cumulative incidence of all diabetes-related complications was lower for EQW compared to glargine except for stroke and amputation due to recurrent foot ulcer: congestive heart failure (31.25% vs. 32.44%), stroke (29.61% vs. 29.50%), myocardial infarction (20.50% vs. 21.16%), angina (15.73% vs. 16.06%), peripheral vascular disease (12.61% vs. 12.73%), amputation recurrent ulcer (1.22% vs. 1.19%). Moreover, EQW was associated with a longer mean time to onset of fi rst complication versus glargine (4.79 vs. 4.59 years). CONCLUSIONS: Long-term projections based on the fi ndings of a recent randomized controlled trial indicate that EQW is likely to improve life expectancy and quality-adjusted life expectancy, reduce complication rates, and delay the time to onset of diabetes-related complications compared with insulin glargine. OBJECTIVES: New classes of antidiabetic medications have been introduced, but details of their use are not well known. In Germany, several measures have been undertaken to limit the usage of analogues in T1D and T2D patients. The aim was to assess the usage patterns of short acting (SA) and basal analogue (BA) insulin in primary care in Germany compared to UK and France. METHODS: Computerized patient data from general medicine practices (IMS Disease Analyzer, 01/2007 to 12/2009) throughout Germany, UK, and France have been analyzed on treatment rates and outcome. RESULTS: In 2009 10,792 insulin patients in France, 20,244 in UK, and 103,238 in Germany were analyzed. The dominance of BA and SA insulins is differing by country and diabetes type (Germany: SA insulins in T2D 40.8% vs. UK 95.8% and France 92.3%). Treatment of T1D with analogous insulins is in general higher compared to T2D (Germany: 56.1% BA in T2D vs. 66.3% in T1D; 40.8% SA in T2D vs. 74.3% in T1D). Usage share of analogous insulins increased over the 3-year period in all three countries (T2D patients, Germany: BA usage 47.6% in 2007 vs. 56.1% in 2009; UK: 78.0% in 2007 vs. 83.0 % in 2009, France 82.2% in 2007 vs. 88.5% in 2009). The analysis of HbA1c values in UK and Germany revealed a higher share of patients with uncontrolled HbA1c values (>7.0) for population treated with analogues (70.8% in Germany) vs. human insulin (68.4%) vs. OAD (42.9%)
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PDB10 PREVALENCE AND OUTCOME OF INSULIN ANALOGUE TREATMENT COMPARING GERMANY, UK, AND FRANCE
Holz B, Schröder-Bernhardi D, Kostev K IMS Health, Frankfurt, Germany OBJECTIVES: New classes of antidiabetic medications have been introduced, but details of their use are not well known. In Germany, several measures have been undertaken to limit the usage of analogues in T1D and T2D patients. The aim was to assess the usage patterns of short acting (SA) and basal analogue (BA) insulin in primary care in Germany compared to UK and France. METHODS: Computerized patient data from general medicine practices (IMS Disease Analyzer, 01/2007 to 12/2009) throughout Germany, UK, and France have been analyzed on treatment rates and outcome. RESULTS: In 2009 10,792 insulin patients in France, 20, 244 in UK, and 103, 238 in Germany were analyzed. The dominance of BA and SA insulins is differing by country and diabetes type (Germany: SA insulins in T2D 40.8% vs. UK 95.8% and France 92.3%). Treatment of T1D with analogous insulins is in general higher compared to T2D (Germany: 56.1% BA in T2D vs. 66.3% in T1D; 40.8% SA in T2D vs. 74.3% in T1D). Usage share of analogous insulins increased over the 3-year period in all three countries (T2D patients, Germany: BA usage 47. 
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DRUG-USE PATTERNS OF INITIALLY PRESCRIBED INSULIN DETEMIR AND INSULIN GLARGINE IN THE NETHERLANDS; A COMPARATIVE ANALYSIS USING PHARMACY DATA FROM IADB.NL
Visser ST 1 , Vegter S 1 , Boersma C 1 , De Grooth R 2 , Postma MJ 1 1 University of Groningen, Groningen, The Netherlands; 2 sanofi -aventis The Netherlands B.V., Gouda, Zuid Holland, The Netherlands OBJECTIVES: Newer long-acting insulin analogs have shown to result in several treatment improvements if compared with NPH insulins. Promising results from clinical trials require confi rmation from observational settings refl ecting potential "real-life" benefi ts. Therefore, the current study aimed to evaluate trends in prescribing (uptake), treatment adherence, and costs of (newer) insulin analogs (e.g., insulin detemir and insulin glargine). METHODS: A drug-utilization analysis was conducted based on using dailypractice prescription data from IADB.nl (one of the databases available in the Mondriaan infrastructure), a dispensing database of 50 pharmacies, covering a Dutch population of 500,000. Drug-utilization data were collected for a 7-year period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) . All patients that received at least one prescription of an insulin analog-defi ned following the "Anatomical Therapeutical Classifi cation" (ATC) as "A10A"-were included for this study. The prevalence and incidence of insulin use were both presented per 1000 population. Survival analysis was conducted to calculate the persistence on different insulin analogs. RESULTS: Preliminary results show a fast increase in the proportion of patients using the newer long-acting insulin analogs with 7% in 2003 to over 30% in 2006. Among patients initiating these newer insulin analogs, use of insulin glargine is more than two times higher compared to use of insulin detemir (507 vs. 190 starters in 2006) . Patients that initiated treatment with long-acting insulin analogs were significantly more adherent to insulin glargine compared to insulin detemir (exact fi gures will be presented during the presentation). CONCLUSIONS: Current preliminary results show an increase in use of long-acting insulin analogs. Of these analogs, insulin glargine is most often initiated and seems to be well-received by patients. Further results will be presented based on a longer follow-up period including differences in HbA1c level dependent dosing and trends in cost development for insulin analogs over time. Also, the potential feature of "channelling" will be investigated.
PDB12 TIME TO OPIOID USE AMONG COMMERCIALLY-INSURED PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN WHO INITIATED DULOXETINE VERSUS OTHER TREATMENTS-A PROPENSITY SCORE APPROACH
Zhao Y 1 , Wu N 2 , Chen SY 2 , Fraser K 2 , Boulanger L 2 1 Eli Lilly & Company, Indianapolis, IN, USA; 2 United BioSource Corporation, Lexington, MA, USA OBJECTIVES: Diabetic peripheral neuropathic pain (DPNP) is often managed using opioids which are subject to tolerance and dependence issues. Newer classes of medications have been approved for DPNP; however, published fi ndings assessing utilization of opioids following treatments with these agents are limited. This retrospective cohort study compared the subsequent use of opioids between commercially insured DPNP patients initiating duloxetine treatment versus other standard of care (SOC) therapies. METHODS: DPNP patients aged 18 to 64 who initiated duloxetine or other SOC treatments (tricyclic antidepressants, venlafaxine, gabapentin, pregabalin) between March 1, 2005 and December 31, 2005 were selected. Initiation was defi ned as a 90-day period without available study medication. The initial dispense date for the study medication was defi ned as the index date. Selected patients had no opioid pill coverage during the 90 days prior to the index date, and no depression, neuralgia, or epilepsy diagnosis in the 12-month pre-index period. Duloxetine and SOC patients were matched via propensity scoring (1:1 ratio), controlling for demographics, comorbidities, prior health-care utilization and costs, and prior medication history. Opioid utilization and health-care costs over the 12-month post-index period were compared between study cohorts. RESULTS: A total of 113 patients in each of the duloxetine and SOC cohorts were matched. Duloxetine-treated patients were less likely to use any opioids versus SOC-treated patients (52.2% vs. 79.6%, P < 0.01) over the 12-month post-index period. Compared with SOC patients, duloxetine patients had, on average, 110 days delay in opioid use, two fewer prescriptions dispensed, 32 fewer days on opioids, and 2064 mg lower morphine equivalent dosage (all P < 0.01) over the 12-month post-index period. Duloxetine patients also had signifi cantly lower total ($19,408 vs. $30,470, P < 0.01) and outpatient costs ($7,606 vs. $15,272, P < 0.01). CONCLUSIONS: Among commercially insured DPNP patients, duloxetine treatment appears to be associated with delayed and reduced opioid utilization and lower healthcare costs than SOC therapies. Despite the progress of clinical trials, clinicians and decision-markers often lack knowledge on how to better promote health-care delivery to patients with T2DM in clinical practice. Outcome research studies can provide effectiveness and economic analysis in actual practice in order to improve clinical performance. OBJECTIVES: To describe the resources used and the costs associated with outpatient treatment of T2DM in the Brazilian PHS. METHODS: This is a cross-sectional analysis of 383 T2DM outpatients treated in fi ve cities by various health plans. Data were collected using info from the previous year by interviewing patients using a validated questionnaire complemented by medical chart review. Direct costs included expenses associated with medications, diagnostic tests, procedures, blood glucose test strips, and health professional visits. Nonmedical direct costs included expenses with diet products. Indirect costs were not assessed. RESULTS: The group had a mean age of 60.5 ± 9.6 years and a mean duration of diabetes of 12.2 ± 8.75 years. Annual outpatient cost of T2DM care was R$10,645.78 per patient, being R$9,534.58 for direct medical costs and R$1,111.20 for nonmedical costs. Costs escalated as duration of diabetes increased (R$8796.68 per patient <9 years vs. R$13,231.74 >19 years of disease; P = 0.05). Those patients with associated microvascular and macrovascular complications (n = 18%) have higher costs (R$15,755.12 per patient) compared to those with microvascular (R$9178.38 per patient; n = 32.4%), macrovascular (R$8726.13 per patient; n = 8.1%), or no complications (R$8246.53 per patient; n = 41.5%). Annual per patient expenses included medications (R$5542.94), blood glucose home monitoring (R$1,014.62), private health professional visits (R$4,264.04), and diet products (R$1,111.20) . Health plans expenses per year were due to exams/ procedures (R$588.02 per patient), medications co-payment (R$1,029.00 per patient), and health professional visits (R$734.12 per patient). CONCLUSIONS: The outpatient care costs assessed reveal that diabetes poses a serious social and economic burden to patients and to Brazilian PHS.
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